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Abstract
Background: Intra-synovial tendon injuries display poor healing, which often results in reduced functionality and
pain. A lack of effective therapeutic options has led to experimental approaches to augment natural tendon repair
with autologous mesenchymal stem cells (MSCs) although the effects of the intra-synovial environment on the
distribution, engraftment and functionality of implanted MSCs is not known. This study utilised a novel sheep
model which, although in an anatomically different location, more accurately mimics the mechanical and synovial
environment of the human rotator cuff, to determine the effects of intra-synovial implantation of MSCs.
Methods: A lesion was made in the lateral border of the lateral branch of the ovine deep digital flexor tendon within the
digital sheath and 2 weeks later 5 million autologous bone marrow MSCs were injected under ultrasound guidance into
the digital sheath. Tendons were recovered post mortem at 1 day, and 1–2, 4, 12 and 24 weeks after MSC injection. For
the 1-day and 1–2-week groups, MSCs labelled with fluorescent-conjugated magnetic iron-oxide nanoparticles (MIONs)
were tracked with MRI, histology and flow cytometry. The 4, 12 and 24-week groups were implanted with non-labelled
cells and compared with saline-injected controls for healing.
Results: The MSCs displayed no reduced viability in vitro to an uptake of 20.0 ± 4.6 pg MIONs per cell, which was
detectable by MRI at minimal density of ~ 3 × 104 cells. Treated limbs indicated cellular distribution throughout the
tendon synovial sheath but restricted to the synovial tissues, with no MSCs detected in the tendon or surgical lesion.
The lesion was associated with negligible morbidity with minimal inflammation post surgery. Evaluation of both treated
and control lesions showed no evidence of healing of the lesion at 4, 12 and 24 weeks on gross and histological
examination.
Conclusions: Unlike other laboratory animal models of tendon injury, this novel model mimics the failed tendon healing
seen clinically intra-synovially. Importantly, however, implanted stem cells exhibited homing to synovium niches where
they survived for at least 14 days. This phenomenon could be utilised in the development of novel physical or biological
approaches to enhance localisation of cells in augmenting intra-synovial tendon repair.
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Background
Tendons connect skeletal muscle to bone and throughout
their length can be either extra-synovial or intra-synovial;
the latter being when the tendon is surrounded by a syn-
ovial tendon sheath that allows almost frictionless move-
ment of the tendon where it wraps around bony
prominences. Intra-synovial tendon disease is not only a
common orthopaedic condition in humans but also affects
domestic mammals that suffer naturally occurring tendon
injuries, such as horses. In humans, the rotator cuff ten-
dons of the shoulder undergo an age-related degenerative
condition which is the third most common musculoskel-
etal complaint that affects 5–30% of adults [1, 2]. Forty to
50% of patients in the UK consult their general practi-
tioners for shoulder pain [3, 4] which poses a significant
socio-economic and treatment challenge. The presence of
a rotator cuff tear has been found to correlate with poorer
shoulder scores [5] and can impair the ability to work or
perform household tasks and result in increased time off
from work [6, 7].
This injury involves the fused tendons of supraspinatus,
infraspinatus, teres minor and subscapularis that are lo-
cated between the subacromial bursa and the scapulohum-
eral joint, and frequently tears enter one or both of these
synovial cavities. Once in communication with the synovial
environment, spontaneous healing is frustratingly poor and
the release of tendon extracellular matrix components
induces a strong inflammatory response [8]. ‘Failed’ healing
is thought to be a consequence of the poorly understood
adverse effects of synovial fluid on tendon healing [9] and
the lack of reparative cells, usually derived from peritendi-
nous sources [10] such as the paratenon which is absent
within intra-synovial portions of tendons.
Current treatment strategies for this disease frequently
deliver ineffective results in terms of functionality and/
or pain. They are routinely treated with injections of a
mixture of local anaesthetic and corticosteroid. Evidence
would suggest that these injections are no more effective
than physiotherapy and result in 40–50% of patients
having persistent or recurrent symptoms after 1 year
[11]. Surgery, often contemplated for persistent cases,
can be unsuccessful in the long term with reported fail-
ure rates between 13 and 68% [12–15]. Not surprisingly,
larger tears are associated with higher incidences of
re-rupture, and re-rupture has been shown to correlate
with poorer outcomes [16, 17]. There is much interest in
the use of the newer biological treatments that can po-
tentially enhance surgical treatments, such as the use of
platelet-rich plasma (PRP) which aims to deliver high
levels of anabolic growth factors to the area. However, in
recently published randomised controlled trials, there
has not been a consistently significant long-term im-
provement with the use of PRP either by intra-tendinous
injection [18, 19] or by augmentation of surgical repairs
[20–28], although the re-tear rate may be reduced [25,
29]. There is therefore a strong unmet clinical need to
restore tendon integrity and avoid surgery.
Intra-synovial deep digital flexor tendon tears in the
horse occur within the digital sheath where the tendon af-
fected is under compression and the tear communicates
with a synovial environment [30], identical to rotator cuff
tears in humans, even though it is in a different anatom-
ical location. Conservative management is also usually un-
successful with affected horses remaining lame and
suffering repeated bleeding and inflammation within the
tendon sheath. Surgical treatments consist of tenoscopic
debridement of the torn tissue but, similar to rotator cuff
disease, have had disappointing outcomes [30, 31].
The application of mesenchymal stromal cells (MSCs)
for tendon healing has demonstrated efficacy in the
treatment of experimentally created tendon injuries in a
number of experimental small animal models [32–34].
However, these small animal models show effective heal-
ing different from large animal models and human clin-
ical disease [35]. MSCs have been used clinically for the
treatment of naturally occurring extra-synovial over-
strain injuries in horses and appear to improve healing
[36–38] but require intra-tendinous administration into
a contained lesion which is not the case in intra-synovial
tendon tears. Therefore, from our knowledge of natur-
ally occurring intra-synovial tendon tears in horses, we
have developed a large animal experimental model utilis-
ing minimally invasive surgery which better replicates
the features of intra-synovial tendon disease to assess
the effectiveness of MSC therapy. The present study
therefore evaluated the distribution and localisation of
autologous adult bone marrow-derived MSCs after
intra-synovial implantation in a sheep deep digital flexor
tendon model of tendon injury. A quadruped’s shoulder
is anatomically and functionally different from the
human shoulder such that current small experimental
models using shoulder tendons, which are neither
compressed nor intra-synovial, are inappropriate to
investigate clinically relevant intra-synovial healing [35].
The sheep DDFT mimics the functional similarities
between the horse DDFT within a tendon synovial
sheath and rotator cuff tears in the human, these being a
similar biomechanical environment (compression), an
intra-synovial location and failed healing with persistent
pain, even after tenoscopic debridement [39]. MSCs
were initially labelled with fluorescence probe conju-
gated superparamagnetic iron-oxide nanoparticles
(MIONs) to enable MRI, histological and flow
cytometry-based evaluations of cellular distribution after
intra-synovial injection, and later the outcome of tendon
healing was assessed grossly and histologically compared
to saline injected controls at 4, 12 and 24 weeks post
implantation.
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Methods
Animals
The study was conducted along the guidelines set by the
ethics committee at the Royal Veterinary College and
under Home Office licence (no. PPL70/6105). Healthy
adult female sheep of the English mule breed were used
for this study, with the following treatments (see
Table 1):
Group 1: 1 day (n = 2), treated with MION-labelled
MSCs.
Group 2: 1–2 weeks (n = 4), three sheep treated with
MION-labelled MSCs and one sheep with Dulbecco’s
phosphate buffered saline (PBS).
Group 3: 4 weeks (n = 12), six sheep treated with non-
labelled MSCs and six sheep with PBS.
Group 4: 12 weeks (n = 16), eight sheep treated with
non-labelled MSCs and eight sheep with PBS.
Group 5: 24 weeks (n = 16), eight sheep treated with
non-labelled MSCs and eight sheep with PBS.
Smaller numbers of animals were used in Groups 1
and 2 because these were initial studies designed to
assess the retention and distribution of labelled MSCs
after implantation at a short time point (Group 1,
physical spread and retention of cells within the
tendon sheath) and after longer time points (Group 2,
engraftment). In addition, the hind limbs of two
sheep from Group 1 were amputated immediately
after euthanasia and assessed for the distribution of
MION-labelled MSCs 1 h after implantation into the
digital flexor tendon sheath.
Tendon injury model
The experimental procedure consisted of three stages:
creation of a surgical lesion in the deep digital flexor
tendon; intra-synovial injection of MSCs or saline
2 weeks after lesion creation; and euthanasia for analyt-
ical examination by MRI (for labelled MSCs) and gross
and histological evaluation of healing (for non-labelled
MSCs) at varying time points after cell injection.
Surgical lesion creation
Each sheep was initially anaesthetised using 2% Rompun
(xylazine) (Bayer Healthcare) and Ketaset (ketamine)
(Fort Dodge Animal Health) at doses of 0.1 and 2 mg/kg
of body mass, respectively, and Hypnovel (midazolam)
(Roche) at a flat rate of 2.5 mg. General anaesthesia was
maintained with isoflurane gas (IsoFlo; Abbott Labs) at
2% of inhaled air. The sheep were maintained in left
lateral recumbency.
Bone marrow aspirates were taken from the iliac crest
of the right pelvis as described previously [40]. Briefly,
approximately 10 ml bone marrow (BM) was aspirated
using an 11G Jamshidi needle (CareFusion, USA) into
syringes containing 100 IU heparin (Multiparin; CP
Pharmaceuticals, Wrexham, UK), which was then
transferred into 5 ml of RPMI-1640 (Sigma-Aldrich) on
ice for ≤ 3 h prior to isolation of MSCs.
The right forelimb hair was clipped and the circumfer-
ence of the distal limb above and below the metacarpo-
phalangeal joint was measured. An Esmarch bandage
was then applied to the limb terminating proximal to
the carpus. A metal rod was inserted into the Esmarch
bandage dorsally and taped to the foot to keep the meta-
carpophalangeal joint in a neutral (straight) position.
The tape was used to entirely cover the foot. After asep-
tic preparation, the limb was draped to expose only the
palmarolateral aspect of the metacarpophalangeal joint.
The digital sheath was distended with 2–3 ml saline
via a 23G needle inserted in the proximal digital sheath
and dorsal to the flexor tendons. Distension of the
collateral pouch immediately distal to the proximal ses-
amoid bones confirmed accurate placement of the nee-
dle. A No. 11 scalpel blade was used to create a small
(2–3 mm) portal into the digital sheath immediately dis-
tal to the proximal sesamoid bone. An arthroscopic
sleeve and blunt-ended obturator (Karl Storz GmbH &
Co. KG, Tuttlingen, Germany) was then inserted into
this portal and gently guided through the fetlock canal.
The obturator was removed and replaced with a 2.4-mm
30° forward-angled arthroscope (Karl Storz). The light
cable, camera and fluid line were connected and the
proximal extent of the sheath was visualised.
Table 1 Experimental design of animal study
Group Time point Number of sheep Surgery BM aspiration MION-
labelled
MSCs
Non-
labelled
MSCs
Gross
assessment
MRI Flow
cytometery
Histological
evaluationControl (PBS) Treated (MSC) Total
1 1 day 0 2 2 ● ● ● ● ● ● ●
2 1–2 week 1 3 4 ● ● ● ● ● ●
3 4 weeks 6 6 12 ● ● ● ● ●
4 12 weeks 8 8 16 ● ● ● ● ●
5 24 weeks 8 8 16 ● ● ● ● ●
BM bone marrow, MION magnetic iron-oxide nanoparticle, MRI magnetic resonance imaging, MSC mesenchymal stem cell, PBS phosphate buffered saline, dots
indicate procedures performed for each group
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The arthroscope was positioned in the proximal sheath
and the site of an instrument portal in the proximal sheath
dorsal to the flexor tendons was established using a 23G
needle. The portal was created with a No. 11 scalpel and
then a 2-mm hook knife (ECTRA II disposable triangle
knife; Smith and Nephew, UK) was introduced through the
portal and positioned at the distal end of the region of the
deep digital flexor tendon not covered by the superficial
digital flexor tendon (Fig. 1a–c). The knife was inserted into
the deep digital flexor tendon and drawn to the proximal
limit of the opening in the superficial digital flexor tendon.
The knife was moved repeatedly proximally and distally to
ensure an even incision with prolapsed fibres, resembling
clinical disease (Fig. 1d). Care was taken to avoid cutting
the adjacent superficial digital flexor tendon.
The portals were closed with single simple interrupted
sutures of 2-0 monofilament nylon and the area covered
in a sterile non-adherent dressing and bandage before
recovery from general anaesthesia in a barn.
MSC implantation
MSCs were implanted at 2 weeks after creation of the le-
sion because of the time required to expand the MSCs
from the bone marrow aspirate, and this allowed the
wound in the synovial sheath to heal to prevent loss of
cells through leakage. After induction of general anaes-
thesia as before, the circumference of the distal limb
above and below the metacarpophalangeal joint was
again measured. The proximal part of the tendon sheath
was prepared aseptically and a 23G arterial catheter was
introduced into the lateral compartment of the sheath
using ultrasound guidance from the palmar aspect of the
limb. The catheter was positioned immediately deep to
the flexor tendons and the stylet withdrawn before 5
million MSCs in 1 ml of PBS were injected into the
sheath of the treatment group and an identical volume
of PBS injected into the control group. Accurate place-
ment was identified by the presence of echogenic air
bubbles present inside the sheath cavity after the injec-
tion. A bandage was applied to the limb and the sheep
allowed to recover from general anaesthesia.
The sheep received two fentanyl (75 μg/h) patches
(Durogesic) 12 h prior to surgery followed by a second
pair 60 h post surgery, which were followed by 0.6 mg
buprenorphine (Vetergesic) 72 h after application of the
second pair of fentanyl patches. The sheep were housed
Fig. 1 A hook knife was used to create a consistent lesion in lateral DDFT using a tenoscopic approach. Positions of instrument portals marked
on intact forelimb by long arrows proximal (hook knife portal) and distal (tenoscope) to ergots (a). Relative position of lesion under sesamoid
bone shown by short arrows in (a) and (b) at euthanasia. Dissected tendon sheath (comprised of DDFT and SDFT complex) reflected back to
expose lesion within normal dorsal opening in SDFT (arrow in b). Scalpel blade positioned between tendons and sesamoid bones. Separated
tendons shown with DDFT on left and SDFT on right (c). Prolapsed fibres from DDFT seen in tenoscope image during surgical generation of
lesion, resembling naturally occurring tendon tears (d). Tissues divided into 10 segments with an additional segment taken proximal to the
sesamoid bones. Identities are elaborated in the accompanying table. DDFT deep digital flexor tendon, SDFT superficial digital flexor tendon
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in individual pens for 1 week and then group housed
with free exercise. Lameness was assessed subjectively
on a daily basis throughout the experiment.
Euthanasia and post-mortem analysis
Sheep were euthanased using an overdose of 20% pento-
barbital at a dose of 0.7 mg/kg (mean volume of 40 ml/
animal) at 1 day, 1–2 weeks after implantation of labelled
MSCs, and at 4, 12 and 24 weeks after implantation of
non-labelled MSCs. The forelimb circumference below
and above the metacarpophalangeal joint was determined
as a measure of local inflammation before the forelimbs
were disarticulated at the carpus for evaluation by MRI
(for labelled MSCs) and later dissected for gross and histo-
logical examination of the tendons and digital sheath.
MRI of sheep forelimbs
Isolated forelimbs were scanned from the distal aspect
of the digits to the mid metacarpal region with a 1.5 T
MR scanner (Philips Intera 1.5 T Pulsar System; Philips
Medical Systems, UK). Images were acquired in the
transverse plane with a 61 mm × 61 mm field of view,
0.55 mm slice thickness and 0.51 mm × 0.51 mm ×
0.55 mm voxel size. Gradient echo sequences (flip angle
15°, TR = 30 ms) were chosen over turbo spin echo
sequences in order to maximise sensitivity to the suscep-
tibility artefact generated by the MION particles, result-
ing in signal void. In order to help differentiate the
hypointense signal generated by MION particles from
other causes of signal void, such as scar tissue (or other
fibrous tissue such as tendons), a dual echo technique
(short TE = 7.2 ms and long TE2 = 17.4 ms) was used.
This provided spatially matching image series in which
the susceptibility artefact associated with MION would
increase in size in the long TE images when compared
to the short TE images, while the size of other causes of
signal void should not be affected.
Gross evaluation of tendons
Amputated forelimbs were dissected to access the
tendon sheath and the digital flexor tendon complex to
separate the overlying SDFT from the DDFT. Six gross
parameters were evaluated in the 4, 12 and 24-week
groups and given a binary score. These parameters were:
signs of inflammatory reaction around the digital flexor
tendon complex (abnormal discolouration); increased
presence of synovial fluid in the sheath using a fine
capillary tube; lesion visibility; closure of the lesion
either by the presence of tissue covering the lesion and/
or the failure of the lesion to open when the tendon was
bent; presence of prolapsed fibres at the lesion site; and
the presence of adhesions (fibrous attachment between
the DDFT and the SDFT).
Histological evaluation of MION-labelled MSC distribution
Tendons were dissected into 12 segments (Fig. 1), of
which seven were fixed in 4% PBS buffered formalde-
hyde for up to 72 h, followed by dehydration and em-
bedding in paraffin (Fig. 1d, e). Sections for histology
were cut on a microtome (Leica RM2125RTF) with
N35HR blades (Feather, Osaka, Japan) at 8 μm thickness
for staining with H&E (Sigma-Aldrich) according to the
supplier’s recommendations.
Flow cytometry for the assessment of MION-labelled MSCs
Four limbs were analysed with flow cytometry for the
distribution of 5 × 106 MION-labelled MSCs after 1 h
(two uninjured hindlimbs from two euthanased sheep)
and two forelimbs 24 h after implantation. After MRI,
hindlimbs were dissected as already described and seg-
mented as shown in Fig. 1 with the accompanying table
identifying the histologically evaluated segments from A
to L. The seven segments selected for formaldehyde fix-
ation and paraffin embedding were divided into two
equal parts. One was used for histology, while the other
was digested as a whole to release cells that may have
engrafted the tissue surfaces using 1 mg/ml collagenase
(type VIII; Sigma-Aldrich) and 1 mg/ml dispase (Gibco,
Life Technologies) for 18 h in growth medium in stand-
ard tissue culture conditions (37 °C in humidified air
and 5% CO2). Proteolytic enzymes were deactivated with
an equal volume of growth medium and tissue-derived
cells isolated and fixed with 4% paraformaldehyde in
PBS for 1 h at room temperature. Cells were then
washed three times and serially analysed for red fluores-
cence emissions on a flow cytometer (BD Facs Calibur).
Data were analysed with FlowJo version 10.
Culture and characterisation of MSCs
Cell culture
MSCs were isolated from bone marrow aspirates as
described previously [40]. Briefly, 10 ml of bone marrow
aspirate in RPMI-1640 was combined with an equal vol-
ume of Minimal Essential Medium Alpha (α-MEM;
Gibco, Life Technologies) supplemented with 15% (v/v)
foetal bone serum (FBS; Gibco) and 1% (v/v) of antibiotics
(penicillin/streptomycin; Gibco) and seeded in a 75-cm2
tissue culture flask (Nunc, Thermo Fisher Scientific, UK)
for 24 h in standard tissue culture conditions. The super-
natant was discarded and non-adherent cells removed by
washing in PBS (Life Technologies) and adherent cells cul-
tured for 7 days. Cells were then passaged and further ex-
panded by re-seeding at a density of 1000 cells/cm2 in
175-cm2 tissue culture flasks (Nunc) in α-MEM medium
for 7 days.
For cell tracking experiments, adherent MSCs were
labelled with Molday ION Rhodamine-B conjugated super-
paramagnetic iron-oxide nanoparticles (BioPal, USA)
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according to the manufacturer’s guidelines. Briefly, the
growth medium of flasks with cells at 70–80% confluence
was supplemented with MIONs to a final concentration of
25 μg/ml and incubated for 24 h. Labelling was compared
with supplementation of protamine sulphate (Sigma, UK)
to a final concentration of 100 μg/ml in an attempt to
enhance MION labelling. Cultures were then washed twice
with PBS to remove free MIONs and the cells detached by
trypsin (Sigma, UK).
A total of 5 × 106 labelled cells suspended in 1 ml PBS
were implanted via catheter into the digital flexor ten-
don sheath as already described. The 4, 12 and 24-week
sheep groups received the same dose of unlabelled cells.
Microscopy of MION-labelled cells
Confocal microscopy was used to visualise MION uptake
by seeding 5 × 104 labelled cells on tissue culture-treated
chamber slides (Nunc, Thermo Fisher Scientific, UK) for
24 h. Samples were fixed in 2% paraformaldehyde (Fischer
Scientific) in PBS (Gibco) and overlaid with DAPI supple-
mented mounting medium (Vector Laboratories) for con-
focal microscopy (Leica 710 confocal microscope).
Quantification of MION uptake by MSCs
Particle uptake was quantified by fluorometric analysis of
MION-conjugated Rhodamine B. Labelled MSCs sus-
pended in PBS were serially diluted (1:2) with an upper
limit of 3.65 × 105 cells in opaque 96-well plates (Nunc). A
standard curve was established by serial dilution of MION
particles in PBS with an upper limit of 25 μg/ml. Fluores-
cence emission intensities were obtained at 647 nm in a
spectrophotometer (Infinite M200 PRO fluorometer;
Tecan, UK). Background-corrected readings of the diluted
cells were interpolated from the MION particle standard
curve to obtain the quantity of MIONs per cell.
Trilineage differentiation
Osteogenic medium comprised Dulbecco’s modified Ea-
gle’s medium (DMEM) low glucose supplemented with
5% FBS, 1% penicillin/streptomycin (Gibco), 10 nM
dexamethasone, 5 mM β-glycerolphosphate and 50 μM
ascorbate (all Sigma Aldrich). DMEM low glucose with-
out osteogenic supplements was used as a control. Cells
were seeded in six-well plates in triplicate at a density of
5000 cells/cm2 in control growth and osteogenic media
for 21 days with bi-weekly medium changes. Cultures
were fixed in 2% paraformaldehyde (Sigma Aldrich) for
20 min before being stained with a solution of 2%
Alizarin Red S in water pH 4.3 (Sigma Aldrich).
Adipogenic medium comprised DMEM low glucose
supplemented with 10% lot-selected FBS, 1% antibiotics
(all Gibco), 0.5 μM 3-isobutyl-1-methyl xanthine
(IBMX), 0.5 μM dexamethasone and 50 μM indometh-
acin (all Sigma). Cells were cultured in 24-well plates in
triplicate for control and adipogenic media with
bi-weekly medium changes for 21 days. Cultures were
washed with PBS and fixed in 2% paraformaldehyde for
20 min before being stained with Oil Red O (Sigma).
Chondrogenic differentiation was conducted according
to Solchaga et al. [41]. Approximately 2 × 105–3 × 105
cells in growth medium were pelleted by centrifuging at
400 × g for 5 min in 15-ml tubes (Nunc) and the
medium replaced with chondrogenic differentiation
medium, which was composed of DMEM high glucose
(Gibco) with 10% (v/v) insulin–transferrin–selenium
(ITS+; BD Biosciences), 100 nM dexamethasone, 1 μM
ascorbate-2-phosphate, 1% sodium pyruvate and 10 ng/
ml TGF-β3 (R&D Systems). Pellets were maintained for
21 days with bi-weekly medium changes, and then fixed
in 2% paraformaldehyde before being processed for par-
affin embedding and sectioned to stain with H&E, alcian
blue and safranin-O.
Statistical analyses
The data were subjected to Student’s t test or one-way
analysis of variance (ANOVA) for significance analysis
(p < 0.05) using GraphPad Prism 6.02. The data were
from at least three independent biological samples and
expressed as the mean ± SD.
Results
Assessment of clinical parameters post surgery
All surgical procedures were undertaken without com-
plications and animals displayed normal recovery with-
out visible lameness or distal limb swelling. A mild
increase in limb circumference above the metacarpopha-
langeal joint was seen post surgery which reduced after
MSC injection, although this was not statistically signifi-
cant (data not shown). No significant change in body
mass was observed during the surgery in either group.
Characteristics of ovine bone marrow MSCs
BM MSCs displayed a spindle-shaped morphology and
formed confluent monolayers (Fig. 2a, b). In CFU-F as-
says, the MSCs formed colonies when seeded at clono-
genic densities with a mean efficiency of 25% (data not
shown) and exhibited adipogenic (Fig. 2c), osteogenic
(Fig. 2d) and chondrogenic (Fig. 2e–g) differentiation.
Effect of MION labelling on MSC growth and trilineage
potential
Confocal microscopy of MSCs consistently demon-
strated the successful uptake of MIONs in all samples
(Fig. 3a, b) which was not enhanced by the addition of
protamine sulphate. MION label was observed to persist
in cells cultured for five population doublings over the
course of 7 days (Fig. 3c) with no significant difference
in the population doubling time between the unlabelled
Khan et al. Stem Cell Research & Therapy  (2018) 9:169 Page 6 of 14
cells (32.29 ± 1.72 h) and labelled cells (34.26 ± 2.98 h, n
= 3). The MSCs were also not affected in their ability to
differentiate in vitro into adipogenic and chondrogenic
lineages (Fig. 3d–i) but they did not demonstrate osteo-
genic differentiation. Fluorometric analyses of MION
content revealed 20.04 ± 4.58 pg iron per cell, which
conferred a sensitivity of 3 × 104 cells in bolus with MRI
(Fig. 3j).
Tracking of MSCs by MRI
The patterns of localisation were similar in all distal
forelimbs injected with MION-labelled MSCs. Areas of
signal void (larger on the long TE images) compatible
with susceptibility artefacts generated by MIONs were
identified in the treated limbs. These predominantly
followed a random distribution in the region of the syn-
ovial membrane of the tendon sheath (Fig. 4). The ten-
don lesion was not identified on MRI. Susceptibility
artefacts were also identified in the region of the surgical
portals (including in PBS control limbs). In some cases,
signal voids were identified close to where the tendon le-
sion had been created, but the limited spatial resolution
of MRI and the lack of background signal from the ten-
dons prevented determining whether the origin of the
susceptibility artefact was located within the tendon or
in the adjacent synovial lining. However, the signal near
the tendinous lesion coincided with the histological lo-
calisation of MIONs in the adjacent synovium.
Gross parameters of the tendon synovial sheath and
lesion
There was minimal inflammation of the digital flexor
tendon sheath. Inflammation was evident in only one
sheep in all groups treated with PBS and one sheep at
only 4 and 12 weeks treated with MSCs (Fig. 5a). Fluid
was visible in two PBS-treated sheep at 4 weeks and one
MSC-treated sheep from each of the three time points
(Fig. 5b). The lesion was macroscopically visible in all
sheep at the 24-week time point (Fig. 5c) and at least
one sheep in each group appeared to be closed upon
Fig. 2 Plastic adherent spindle-shaped cells from bone marrow aspirates (a) formed confluent monolayers by 7 days (b). Adipogenic Oil Red
O-stained MSCs after 14 days of in-vitro differentiation (c). Osteogenic differentiation stained with Alizarin Red S staining (d). Chondrogenic
differentiation with H&E (e), alcian blue (f) and safranin-O (g) staining
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gentle manipulation (Fig. 5d). However, the lesion had
overlying fibrous tissue in at least one sheep from both
treatments at all time points (Fig. 5e). Prolapsed fibres
were visible in 2/6, 6/8 and 2/8 of the PBS-treated sheep
at all three time points compared to 6/6 and 3/8 sheep
treated with MSCs at 4 and 24 weeks (Fig. 5e). The
MSC-treated sheep at 12 weeks displayed no prolapsed
fibres (Fig. 5e). Only one sheep in the PBS-treated group
and one sheep in the MSC-treated group were found to
have adhesions between the DDFT and SDFT (Fig. 5f ).
Histological examination of the SDFT and DDFT for MSCs
Histological examination of sheep treated with
MION-labelled MSCs indicated Prussian blue (to stain
for iron) positive cells within the palmar synovial tissue
(segment J in Fig. 1e) on the palmar surface of the SDFT
(Fig. 6a) and the dorsal synovial tissue (segment K in
Fig. 1d) constituting the opposing dorsal synovial tissue
to the DDFT (Fig. 6b). However, labelled cells were
neither within the synovial covering of the deep digital
flexor tendon nor in the tendon lesion (Fig. 6c). The Prus-
sian blue positive cells were detected as non-homogeneous
clusters engrafted within the synovium and distinct
from iron associated with red cells within blood ves-
sels (Fig. 6a, b).
Histological evaluation of transverse sections of the
deep digital flexor tendon in sheep treated with
non-labelled MSCs showed the persistence of the tendon
lesion in all groups at 4, 12 and 24 weeks (Fig. 7a–g).
These included those tendons which appeared closed on
gross examination (Fig. 5c), indicating an absence of ten-
don healing at 4, 12 and 24 weeks post implantation.
Engraftment of MSCs with the synovium by flow
cytometry
The number of cells isolated as a result of whole tissue
digestion ranged from 4000 to 25,000 cells per segment.
The cells isolated from sheep implanted for 1 h showed
an absence of MION-related fluorescence in the lateral
and medial DDFT segments A and B (Fig. 8a, b).
MION-related fluorescence was detected in cells isolated
from only one of the two sheep for lateral and medial
SDFT segments F and G after 1 h (Fig. 8c, d). However,
both sheep displayed MION fluorescence in cells iso-
lated from SDFT bifurcation (Fig. 8e) and at the level of
the sesamoid bones (Fig. 8g) after 1 h. Cells isolated after
24-h implantation displayed MION fluorescence at the
Fig. 3 Confocal micrographs of unlabelled MSCs (a) and MION-labelled MSCs (b) (blue DAPI, red Rhodamine B). Labelled MSCs after 7 days in
culture showing persistence of MIONs (c). Adipogenic differentiation of MSCs with Oil Red O staining with control cells (d) and induced cells
(e) along with Prussian blue stain (f). H&E staining of a chondrogenic pellet of MION-labelled MSCs (g) that also stained positively for alcian blue
(h) and Prussian blue stain (i). MR imaging of MION-particles and MION-labelled cells embedded as a bolus in 1% agarose gel to assess sensitivity
of detection (j). MION magnetic iron-oxide nanoparticle
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tendon bifurcation site in both sheep (Fig. 8h) but not in
the DDFT and SDFT segments and sesamoids (Fig. 8i–l).
The percentage of cell retention was not quantified since
only the outer surfaces of the tissue samples were
digested to release cells adhered on the outside.
Discussion
The present study sought to evaluate the distribution and
localisation of MSCs following implantation within the
digital tendon synovial sheath and their ability to heal an
experimentally induced tendon lesion. The use of a hook
knife with a fixed length and the naturally occurring gap
in the overlying SDFT resulted in a highly reproducible
intra-synovial surface lesion with prolapsed fibres that
resembled naturally occurring tendon tears. The use of
minimally invasive surgery in this model produced min-
imal inflammation and consequently low morbidity in the
sheep, as evidenced by the lack of lameness and synovial
effusion. Most interestingly, the created lesion failed to
heal, even after 6 months, which is unusual in experimen-
tal surgical models but is a characteristic of natural
intra-synovial tendon disease where lesions remain
unaltered for many months. Thus, this study has
demonstrated a novel model that reproduces many of the
features of naturally occurring intra-synovial tendon dis-
ease. The absence of significant surgical trauma associated
with this disease model makes this model particularly
appropriate for investigating novel treatment strategies for
intra-synovial tendon disease, such as rotator cuff tears.
The MSCs were isolated based on whole bone marrow
plating, which is a relatively recent method applied for
MSC recovery and expansion compared to the widely
accepted method of Ficoll-based density centrifugation.
Our previous work has shown that whole bone marrow
plating could yield cultures with almost uniform positive
staining for MSC-related antigens, although a small
number of CD34 and CD45 positive cells were detect-
able by flow cytometry [40]. This method was an easier
and reliable way to isolate MSCs and was therefore used
for this study. MION labelling was not found to affect
MSC characteristics including colony forming ability,
proliferation and trilineage differentiation ability.
MIONS were used in an attempt to track the location of
MSCs on MRI. MIONs contain iron and as this poten-
tially may affect MSC behaviour we attempted to evaluate
this in vitro, and were able to show no significant effect of
Fig. 4 MRI of distal aspect of forelimb. Top row: scan site on a sagittal image. Second and third rows: control limb. Fourth and fifth rows: treated
limb. Second and fourth rows: short TE scan. Third and fifth rows: long TE scan. Left columns: images obtained proximal to proximal sesamoid
bones. Middle columns: images obtained just distal to proximal sesamoid bones. Right columns: images obtained along distal aspect of proximal
phalanx. Susceptibility artefacts (confirmed as such due to larger size on long TE images, compatible with presence of MION particles) identified
at multiple sites in treated limb, but not in control limb. Proximally, susceptibility artefact outside tendon sheath (large black arrows) in region of
injection site. Just distal to proximal sesamoid bones, susceptibility artefact identified at several sites in lateral tendon sheath (solid narrow white
arrows). Distally, susceptibility artefact identified in lateral (solid narrow black arrow) and medial tendon sheath (dashed narrow black arrow). TE
echo time
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population doubling or adipogenic and chondrogenic dif-
ferentiation. However, osteogenic differentiation did ap-
pear to be adversely affected and this may be due to the
presence of intracellular iron which has recently been
shown to inhibit osteogenesis [42]. For this reason, the as-
sessment of healing was done at the longer time points
with unlabelled cells.
MIONs are a negative contrast material, resulting in
signal void (hypointensity) in MRI. Gradient echo
sequences were chosen in order to maximise the sensi-
tivity to this artefact, and dual echo was used in order to
specifically differentiate susceptibility artefacts from
other causes of signal void (such as scar tissue). The
main limit of this method is the difficulty to detect a
hypointense signal void created by MIONs against the
predominantly hypointense background signal of ten-
dons due to the alignment of water molecules with the
collagen. In order to track cells in tendons, the use of
positive contrast material may be necessary or the magic
angle artefact should be used [43], but specificity could
be limited as tears can also result in increased signal
within the tendons. Evaluation of quantitative methods,
such as T2 or T1 mapping, was beyond the scope of this
study. The analysis showed a non-generalised distribu-
tion of cells throughout the sheath with higher concen-
tration in the region of tendon sheath cavity and
synovial lining. The histology corroborated MRI find-
ings, with Prussian blue positive cells identified in the
synovial tissue sections from all implanted animals.
Interestingly, the lesion was not visible on MRI as a re-
sult of the limited resolution of the MRI and the pres-
ence of hyperintense foci, most likely representing
interfascicular matrix, visible in all tendons including
non-injected control limbs, further confirming the lack
of inflammation within the tendon as a result of the sur-
gical lesion.
The implanted MSCs did not appear to home to the
tendon lesion based on both MRI and histology of
Fig. 5 Gross parameters recorded during dissection process indicate only a few animals to have visible inflammation (a) with low quantities of
fluid within sheath (b). Lesion macroscopically visible in most sheep at 4, 12 and 24 weeks (c). Dissected tendon gently manipulated by bending
in axial plane to determine whether two surfaces of lesion could be separated as a macroscopic sign of healing. At least one sheep in each
group showed closure (d) and at least one sheep had overlying fibrous tissue but with presence of prolapsed fibres less consistent (e). Adhesions
were only visible in one sheep (control) at 24 weeks and one sheep (MSC treated) at 4 weeks (f). BM MSC bone marrow mesenchymal stem cell,
PBS phosphate buffered saline
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Fig. 6 Montage representing whole section of SDFT bifurcation with dorsal synovium (H&E), with higher magnification showing presence of Prussian
blue positive cells (white arrowheads sowing some examples) (a) which were also detected at different locations within the ventral synovial tissues
(open arrowheads and blue stained cells in high power images) (b). Labelled cells were not detected in contra-lateral forelimb nor in PBS-injected
tendons. Labelled cells not were detected within DDFT or lesion (c). These observations were consistent in all sheep implanted with cells. Arrows
shown along length of lesion in (c). SDFT superficial digital flexor tendon
Fig. 7 Images of transverse DDFT tendon sections of PBS-treated (a, c, e) and MSC-treated (b, d, f) sheep at 4, 12 and 24 weeks post implantation,
respectively. Lesion persisted in all samples at 4 weeks (a versus b), 12 weeks (c versus d) and 24 weeks (e versus f). Arrow shown along length of
lesion. Scale bar = 1 mm
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MION-labelled MSCs, which explains the lack of a
detectable beneficial effect on healing at the later time
points. This is in contrast to lesions created in the core
of the sheep DDFT within the extra-synovial portion
where retention of MSCs can be observed [44]. Interest-
ingly, in our intra-synovial model, cells had adhered as
clusters at specific sites within the synovial membrane
tissue, suggesting that implanted MSCs attach to specific
preferential stem cell niches within the synovium. It is
not clear what factors enable the MSCs to engraft into
this location, nor why they appear as clusters, although
the presence of receptors on the synovial membrane and
subsequent proliferation in situ after engraftment remain
the most likely explanations. This adherence appears to
be rapid since no labelled cells were recovered from the
swabs taken on the synovial fluid 1 h after implantation.
The use of pre-differentiated MSCs into a tendon pro-
genitor cell may overcome the limitation to home into
Fig. 8 Flow cytometry graphs of MION-labelled MSCs isolated from tissue segments from two sheep at 1 h (a–g) and 24 h (h–l) after implantation.
Tissue segments were dissected and adherent cells released by mild enzymatic digestion. a, k Distal lateral DDFT (segment A). b Distal medial DDFT
(segment B). c, j Distal lateral SDFT (segment F). d, l Distal medial SDFT (segment G). e, h SDFT bifurcation (segment J). f Ventral synovium (segment K).
g, i Sesamoid bones, distal to segment K. MION-labelled cells were detectable in segment J of both sheep at 1 h (e) and 24 h (h) post implantation.
Cells were detectable at the level of proximal sesamoid bones (distal to segment K) in both samples at 1 h (g) but not at 24 h (i) post implantation.
DDFT segments did not display MION-related fluorescence at either time point in both samples nor where cells were recovered from the synovial
cavity (sample L). Sample identities are elaborated in Fig. 1 accompanying table
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the tendon but this will need to be tested in the future.
Although a dose response to applied MSCs was not
performed in this study, it is possible that higher doses
of cells may have promoted homing or closure of the le-
sion. However, given the rapid dispersion of the cells
after injection and the absence of cells in either the
SDFT or the DDFT, we propose that cell retention
rather than higher doses may be more effective.
Conclusions
The use of minimally invasive techniques in this model
produces a non-healing intra-synovial tendon lesion in a
tendon under compression which more accurately mimics
the clinical situation of rotator cuff disease in humans.
Furthermore, this model is associated with minimal mor-
bidity and is ideal for evaluating novel biological therapies
for augmenting intra-synovial tendon repair. However,
intra-synovially administered bone marrow-derived MSCs
did not appear to home to a tendon lesion and did not
promote healing. We therefore hypothesise that physical
or biological techniques to localise MSCs to or within the
tendon lesion will be necessary to enable any therapeutic-
ally beneficial effect of MSCs.
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